Custom-Made vaccine tested in fight against pancreatic cancer
NCT ID NCT04161755
Summary
This early-stage trial is testing the safety of a new, personalized treatment approach for pancreatic cancer. After surgery to remove the tumor, patients receive an immunotherapy drug followed by a vaccine designed specifically for their cancer, and then standard chemotherapy. The study aims to see if this combination is safe and tolerable for 29 patients with a specific type of resectable pancreatic cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities)
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau (All Protocol Activities)
Rockville Centre, New York, 11570, United States
-
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York, 10604, United States
Conditions
Explore the condition pages connected to this study.